Advertisement

Medical Oncology

, Volume 28, Issue 4, pp 1589–1595 | Cite as

Partial trisomy 11, dup(11)(q23q13), as a defect characterizing lymphomas with Burkitt pathomorphology without MYC gene rearrangement

  • Barbara Pienkowska-GrelaEmail author
  • Grzegorz Rymkiewicz
  • Beata Grygalewicz
  • Renata Woroniecka
  • Paulina Krawczyk
  • Katarzyna Czyz-Domanska
  • Jan Walewski
Original Paper

Abstract

Burkitt lymphoma (BL) is an aggressive non-Hodgkin lymphoma characterized by specific morphological and immunophenotypic features. The basic genetic feature of BL is the rearrangement of MYC gene, visible as t(8;14)(q24;q32) translocation or its variant. However, some lymphomas with characteristic BL morphology are nowadays diagnosed as B-cell lymphoma unclassifiable with features intermediate between DLBCL and BL (Inter-DLBCL/BL) for biological or clinical reasons. We present four lymphomas without the MYC rearrangement presented typical Burkitt morphology, FCM immunophenotype with some deviations when compared to a typical BL. The cases were finally diagnosed as Inter-DLBCL/BL. All of them presented a recurrent abnormality within the chromosome 11: dup(11)(q23q13). We suppose that the dup(11)(q23q13), in absence of the MYC gene rearrangement, is connected with borderline lymphomas with a morphology similar or identical to that of the Burkitt lymphoma. Identifying such an aberration may be helpful in the diagnostics of Inter-DLBCL/BL eventually forming a distinct subgroup of lymphomas.

Keywords

Non-Hodgkin’s lymphoma Burkitt morphology Chromosome aberrations FISH 

References

  1. 1.
    Dave SS, et al. Lymphoma/leukemia molecular profiling project. Molecular diagnosis of Burkitt’s lymphoma. N Engl J Med. 2006;354:2431–42.PubMedCrossRefGoogle Scholar
  2. 2.
    Kluin PM. B-cell lymphoma, unclassifiable with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC; 2008. p. 265–6.Google Scholar
  3. 3.
    Leoncini L. Burkitt lymphoma. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC; 2008. p. 262–4.Google Scholar
  4. 4.
    Sevilla DW, et al. Clinicopathologic findings in high-grade B-cell lymphomas with typical Burkitt morphologic features but lacking the MYC translocation. Am J Clin Pathol. 2007;128(6):981–91.PubMedCrossRefGoogle Scholar
  5. 5.
    Harris NL, Horning SJ. Burkitt’s lymphoma—the message from microarrays. N Engl J Med. 2006;354:2495–8.PubMedCrossRefGoogle Scholar
  6. 6.
    Patte C, et al. Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescent: it is possible to reduce treatment for the early responding patients. Blood. 2007;109:2773–80.PubMedGoogle Scholar
  7. 7.
    Margath IT, et al. An effective therapy for both undifferentiated (including Burkitt’s) lymphomas and lymphoblastic lymphomas in children and young adults. Blood. 1984;63:1102–11.Google Scholar
  8. 8.
    Diebold J, Jaffe ES, Raphael M, Warnke RA. Burkitt lymphoma. In: Jaffe E, Harris NL, Stein H, Vardiman JW, editors. Pathology and genetics: tumours of haematopoietic and lymphoid tumours. Lyon: AIARC Press; 2001. p. 181–4.Google Scholar
  9. 9.
    Blum KA, Lozanski G, Byrd JC. Adult Burkitt leukemia and lymphoma. Blood. 2004;104:3009–20.PubMedCrossRefGoogle Scholar
  10. 10.
    Hecht JL, Aster JC. Molecular biology of Burkitt’s lymphoma. J Clin Oncol. 2000;18:3707–21.PubMedGoogle Scholar
  11. 11.
    Chan NP, Ma ES, Wan TS, Chan LC. The spectrum of acute lymphoblastic leukemia with mature B-cell phenotype. Leuk Res. 2003;27:231–4.PubMedCrossRefGoogle Scholar
  12. 12.
    Perkins AS, Friedberg JW. Burkitt lymphoma in adults. Hematology Am Soc Hematol Educ Program. http://asheducationbook.hematologylibrary.org/cgi/content/full/2008/1/341.
  13. 13.
    Hummel M, Bentink S, Berger H. A biological definition of Burkitt’s lymphoma from transcriptional and genomic profiling. N Engl J Med. 2006;354:2419–30.PubMedCrossRefGoogle Scholar
  14. 14.
    Shaffer LG, Tommerup N, editors. ISCN: an international system for human cytogenetic nomenclature. Basel: S. Karger; 2005.Google Scholar
  15. 15.
    Mitelman Database of Chromosome Aberrations in Cancer, The Cancer Genome Anatomy Project http://cgap.nih.gov/chromosomes/Mitelman. Accessed 14 July 2009.
  16. 16.
    Koduru PRK, Offit K, Jhanwar SC. Molecular analysis of structural chromosome changes affecting chromosome band 11q23. Dis Markers. 1989;7:145–52.PubMedGoogle Scholar
  17. 17.
    Leucci E, et al. MYC translocation-negative classical Burkitt lymphoma cases: an alternative pathogenetic mechanism involving miRNA deregulation. J Pathol. 2008;216:440–50.PubMedCrossRefGoogle Scholar
  18. 18.
    Jerkeman M, et al. Prognostic implication of cytogenetic aberrations in diffuse large B-cell lymphomas. Eur J Haematol. 1999;62:184–90.PubMedCrossRefGoogle Scholar
  19. 19.
    Espinet B, Florensa L, Salido M, Solé F. MLL intrachromosomal amplification in a pre-B acute lymphoblastic leukemia. Haematologica. 2003;88(2):EIM03.PubMedGoogle Scholar
  20. 20.
    Deisch J, et al. Segmental tandem triplication of the MLL gene in an intravascular large B-cell lymphoma with multisystem involvement: a comprehensive morphologic, immunophenotypic, cytogenetic, and molecular cytogenetic antemortem study. Arch Pathol Lab Med. 2009;133(9):1477–82.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Barbara Pienkowska-Grela
    • 1
    Email author
  • Grzegorz Rymkiewicz
    • 2
  • Beata Grygalewicz
    • 1
  • Renata Woroniecka
    • 1
  • Paulina Krawczyk
    • 1
  • Katarzyna Czyz-Domanska
    • 3
  • Jan Walewski
    • 3
  1. 1.Cytogenetic LaboratoryMSCM Cancer Centre and InstituteWarsawPoland
  2. 2.Flow Cytometry LaboratoryMSCM Cancer Centre and InstituteWarsawPoland
  3. 3.Department of Lymphoprolipherative DiseaseMSCM Cancer Centre and InstituteWarsawPoland

Personalised recommendations